key: cord-0756596-y0xnz9vi
authors: Wu, Weining; Roy, Polly
title: Sialic Acid Binding Sites in VP2 of Bluetongue Virus and Their Use during Virus Entry
date: 2022-01-12
journal: Journal of virology
DOI: 10.1128/jvi.01677-21
sha: cb8246b44c378fe386ffa34034d337c4856e6fba
doc_id: 756596
cord_uid: y0xnz9vi

Bluetongue virus (BTV), a member of the Orbivirus genus, is transmitted by biting midges (gnats, Culicoides sp.) and is one of the most widespread animal pathogens, causing serious outbreaks in domestic animals, particularly in sheep, with high economic impact. The non-enveloped BTV particle is a double-capsid structure of seven proteins and a genome of 10 double-stranded RNA segments. Although the outermost spike-like VP2 acts as the attachment protein during BTV entry, no specific host receptor has been identified for BTV. Recent high-resolution cryo-electron (cryoEM) structures and biological data have suggested that VP2 may interact with sialic acids (SAs). To confirm this, we have generated protein-based nanoparticles displaying multivalent VP2 and used them to probe glycan arrays. The data show that VP2 binds α2,3-linked SA with high affinity but also binds α2,6-linked SA. Further, Maackia amurensis lectin II (MAL II) and Sambucus nigra lectin (SNA), which specifically bind α2,3-linked and α2,6-linked SAs, respectively, inhibited BTV infection and virus growth in susceptible sheep cells while SNA alone inhibited virus growth in Culicoides-derived cells. A combination of hydrogen deuterium exchange mass spectrometry and site-directed mutagenesis allowed the identification of the specific SA binding residues of VP2. This study provides direct evidence that sialic acids act as key receptor for BTV and that the outer capsid protein VP2 specifically binds SA during BTV entry in both mammalian and insect cells. IMPORTANCE To date no receptor has been assigned for non-enveloped bluetongue virus. To determine if the outermost spike-like VP2 protein is responsible for host cell attachment via interaction with sialic acids, we first generated a protein-based VP2-nanoparticle, for the multivalent presentation of recombinant VP2 protein. Using nanoparticles displaying VP2 to probe a glycan array, we identified that VP2 binds both α2,3-linked and α2,6-linked sialic acids. Lectin inhibitors targeting both linkages of sialic acids showed strong inhibition to BTV infection and progeny virus production in mammalian cells; however the inhibition was only seen with the lectin targeting α2,6-linked sialic acid in insect vector cells. In addition, we identified the VP2 sialic acid binding sites in the exposed tip domain. Our data provides direct evidence that sialic acids act as key receptors for BTV attachment and entry in to both mammalian and insect cells.

between its animal hosts, and often causes serious periodic outbreaks particularly in sheep and cattle, with high economic impact.

BTV is structurally highly complex with a genome of 10 double-stranded RNA (dsRNA) segments (S1-S10) enclosed by four layers of different proteins. Ten genomic segments encode seven structural proteins (VP1-VP7) and four non-structural proteins (NS1-NS4). The outer capsid is formed by two consecutive layers of proteins, the outermost VP2 and the slightly less exposed VP5, and both proteins attach to an underlying VP7 layer which coats the VP3 core. The remaining three structural proteins (VP1, VP4, and VP6) form the enzymatic interior of the virus together with genomic RNA. Recent atomic-resolution structures have revealed that 120 VP2 molecules form 60 trimers and that each monomer consists of three distinct domains (hub, body, and tip), displayed as triskelion-like spikes, each blade of which (viz., the tip domain) protrudes 4 nm from the surface of the particles while the hub and body base sits on the underlying VP5 trimers (1) . The structural configuration of VP2 is consistent with it biological functions, as it is the host attachment protein, and also the viral antigenic determinant of serotype specificity (2) . Upon attachment, VP2 facilities the clathrin-mediated endocytosis of virion particles. In the early endosome, VP2 senses the low pH via a unique zinc finger and consequently changes conformation and dissociates from the virion particle. The remnant particle, with VP5 still attached, then proceeds to the late endosome where the acidic pH triggers drastic conformation change to enable membrane penetration and release of the viral core into the cytoplasm (1, 3, 4) .

While much molecular and structural study has been undertaken on the action of VP2 and VP5 in cell entry, to date no receptor has been assigned for BTV or any other orbiviruses, although our previous studies have suggested that cell surface sialic acids, and possibly additional receptors may be involved (1, 5) . Arboviruses generally do not rely on a single specific host receptor-rather they use common cellular ligands, such as Ca 21 -dependent (C-type) lectins, immunoglobulin fragment crystallisable-gamma (Fcg) receptors, and tyrosine-protein kinase receptor Axl (6) .

Sialic acids are known to be involved for attachment and entry of other non-enveloped and enveloped viruses, such as adenoviruses, rotaviruses, and influenza viruses (7) (8) (9) and our previous studies indicated that BTV binds glycophorin A, which contains high levels of sialic acids (10) . Further, the lectin wheat germ agglutinin (WGA), which binds specifically to N-Acetyl-d-glycosamine (GlcNAc), had been shown to block BTV binding to the cells (5, 10) . However, there is no direct evidence that VP2 binds sialic acids and if so what types of sialic acid may serve as BTV ligands during virus entry.

In this report, we seek to determine that sialic acid is a cellular ligand for BTV and that VP2 is directly responsible for this interaction. To do this, we first generated recombinant VP2 as protein nanoparticles (Fc-VP2-PNP) to increase avidity through multivalent interactions as reported for coronavirus spike protein (11) . Using these nanoparticles, it was possible to obtain direct evidence of specific interaction between VP2 and specific sialic acids, particularly its specificity for a2,3 and a2,6 linkages. Further, we determined the sialic acid preference used by BTV for mammalian versus vector Culicoides cells. Lastly, we identified the sialic acid binding sites and the key residues of VP2 responsible for virus attachment to the host cells.

Multivalent presentation of recombinant VP2 protein on the nanoparticles. BTV is capable of agglutination of a variety of animal and human red blood cells (RBCs) in vitro. The hemagglutination (HA) specificity of certain erythrocytes has been reported for different BTV serotypes with variable intensity, indicating the activity is serotype dependent (12, 13) . Our previous use of recombinant purified BTV-10 VP2 confirmed that VP2 is responsible for binding to glycophorin on RBCs and hemagglutanation activity (10) . However, the hemagglutination activity of purified VP2, as a soluble protein, is generally very low when compared with the virion particle (10) and is too weak to investigate the interaction of VP2 with sialic acid receptors (14) . To overcome the low affinity of VP2 binding to sialic acids, we designed multicopy VP2 self-assembled into a nanoparticle similar to that reported for MERS-CoV S1 protein, which then showed enhanced hemagglutination activity (11) . The nanoparticle is a 60-meric self-assembled particle of lumazine synthase (LS) from the hyperthermophile Aquifex aeolicus. The N-terminus of LS is fused with domain B of protein A (pA) from Staphylococcus aureus which has a high affinity for the Fc fragment of human IgG (15) . Accordingly, a construct was made to express the pA-LS nanoparticle protein as a secreted protein from transfected HEK293T cells with an added N-terminal streptavidin tag to facilitate affinity purification. The purified nanoparticles were analyzed by SDS-PAGE followed by Coomassie blue staining. The protein content of the nanoparticles showed a monomer molecular mass of ;25 kDa, as predicted (Fig. 1A) . To allow binding of VP2 to the nanoparticle, the amino terminus of VP2 was tagged with the Fc sequence from human IgG and a streptavidin tag II (WSHPQFEK) for affinity purification and the subsequent fusion protein expressed using the baculovirus expression system. Analysis of purified Fc-VP2 protein by SDS-PAGE showed that VP2 largely existed in its trimeric form, however, in the presence of reducing agent or heat treatment the protein converted to the monomeric form (Fig. 1B) . To prepare VP2-nanoparticles, 6 mg of pA-LS nanoparticles and 20 mg of Fc-VP2 were incubated for 30 min at room temperature and the formation of VP2 and nanoparticle complex was analyzed by glycerol gradient ultracentrifugation. A clear shift was apparent of Fc-VP2 from the top layer to the middle-lower layer of the gradient in the presence of pA-LS compared with Fc-VP2 in the absence of pA-LS, indicating the formation of a nanoparticle complex (Fig. 1C) . We calculated the amounts of pA-LS and Fc-VP2 in fractions 7 to 10 by densitometry, suggesting a molar ratio between 1:0.2 to 1:0.29 of pA-LS and Fc-VP2 in the complex.

VP2-nanoparticles (Fc-VP2-PNPs) enhance the hemagglutination and the glycophorin binding activities. To examine if the VP2 nanoparticle could hemagglutinate sheep RBCs, a combination of different amount of Fc-VP2 and 1 or 2 mg of pA-LS was optimized for hemagglutination activity. The combination of 1 mg pA-LS and 1.25 mg Fc-VP2 (equivalent to a molar ratio of 1:0.25) exhibited the maximum hemagglutination (HA) titer of 512 with sheep RBCs. In contrast, nanoparticles lacking Fc-VP2, as a control, failed to show any hemagglutination activity ( Fig. 2A) . When 2.5 mg of Fc-VP2 was incubated with decreasing amounts of nanoparticles (1, 0.5, 0.25, and 0.125 mg) the HA titers also decreased. However, increasing the Fc-VP2 amount in the nanoparticles to 4 mg did not significantly increase the HA titer, indicating that nanoparticles have been saturated for their maximum binding capacity (Fig. 2B) . The optimized combination of Fc-VP2 and pA-LS, which exhibited the maximum HA titer, suggested that approximately five of Fc-VP2 trimers can be accommodated on each of the 60-mer pA-LS nanoparticles forming Fc-VP2-PNP. Fc-VP2 alone without nanoparticles exhibited a very low HA titer, of only ;4 units ( Fig. 2B ) consistent with a previous study (10) and an inability to cross-link the RBCs. Thus, nanoparticles presenting VP2 have significantly increased hemagglutination activity.

To determine whether the multivalent Fc-VP2 nanoparticles could increase the interaction of VP2 to human glycophorin A, the predominant sialoglycoprotein on human RBCs, we used an ELISA. A glycophorin A-coated 96-well ELISA plate was incubated with mixtures of 2 mg pA-LS and different amounts of purified Fc-VP2 or Fc-VP2 alone as before. While binding of VP2 alone was minimal, binding of the Fc-VP2-PNPs was significantly high and was dose-dependent, with the maximum binding at the molar ratio about 1:0.2 of pA-LS and Fc-VP2 (Fig. 2C ). These data confirm that VP2-nanoparticles significantly increase sialic acid binding capacity when compared to VP2 protein alone.

Does VP2 recognize specific sialic acid for cell attachment? The enhanced sialic acid binding affinity of Fc-VP2-PNPs led us to use these particles to identify the VP2 preference for specific sialic acid linkages. To this end, we probed an array of 562 glycans (16) with the Fc-VP2-PNPs and compared the binding profile with uncoated PNPs alone as control. As shown in the Fig. 3 , the results showed clearly that there is a preferential binding to sialylated glycans by the Fc-VP2-PNPs complex compared with the PNPs alone, which did not bind to any sialylated glycan structures (Table S1 ), indicating the specific interaction between VP2 and sialylated glycans.

Based on the glycan array data, VP2 bound to both Neu5Ac and Neu5Gc sialoglycans with a preference for Neu5Ac (Fig. 3) . Further, it preferentially bound to the short, unbranched a2,3-linked sialotrisaccharides (glycan #45 and #277) and a2,6-linked (glycan #267, #266, and #278) sialoside, as well as to long, branched a2,3-linked sialosides with a minimum extension of an N-Acetyllactosamine (LacNAc) tandem repeats. A low level of binding was observed to a number of a2,3/a2,6-linked and a2,8-linked sialosides but the preferential binding was clearly to a2,3-linked sialosides (Fig. 3) . Our data are consistent with earlier reports that both a2,3and a2,6-linked sialic acids could be utilized as receptors by BTV for attachment during its entry into the host cells.

BTV infection is inhibited by a2,3and a2,6-linked sialic acid binding lectin competitors. To investigate further if BTV used different sialic acids for different host cells, a series of mammalian cells were examined for BTV infection in the presence of specific lectin inhibitors, Maackia amurensis lectin II (MALII), which binds a2,3-sialic acid and SNA, which prefers to bind a2,6-sialic acid. Prior to an assessment of SA specificity, we first examined the distribution of a2,3and a2,6-linked sialic acids on the surface of three different mammalian cells, BSR (BHK-21 derived) cells that are used for BTV infection routinely in the laboratory and the two different BTV-susceptible host cell lines, PT (sheep) cells and MDBK (steer) cells by immunofluorescence microscopy using FITC-conjugated MALII and SNA. All three types of cells showed a predominant distribution of a2,6-linked sialic acids over a2,3-linked sialic acids, although PT cells exhibited abundant distribution of both a2,3and a2,6-linked sialic acids compared with the other two mammalian cell lines (Fig. 4A) . The data was further confirmed by flow cytometry analyses. As shown in Fig. 4B , a2,6-linked sialic acids of all three cell lines exhibited higher level of median fluorescence intensity (MFI) of a2,6-linked sialic acids compared to that of a2,3-linked sialic acids.

All three cells were then preincubated with 100, 200, 400, 600, or 800 mg/mL of MALII or SNA, and a combination of both lectins at 400 mg/mL of each lectin, prior to infection with BTV. An MTT (2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide) cytotoxicity assay showed that there was no significant cytotoxicity at the concentrations tested (Fig. 5A) . Both MALII and SNA lectin competitors inhibited progeny virus production in a dose-dependent manner in all three types of cells. At 400 mg/mL concentration, MALII showed approximately 63%, 88%, and 59% inhibition of virus infection in BSR, PT, and MDBK cells, respectively, while SNA showed more than 90% inhibition in all cells. With the combination of both lectins at the concentration of 400 mg/mL, inhibition was almost 100% in all three mammalian cell lines (Fig. 5B) . These results are consistent with the observed distribution of a2,3and a2,6-linked sialic acids in the three cell lines, and suggest that BTV could take advantages of both type of sialic acids for entering mammalian host cells. To prove that blocking cell surface sialic acids prevents viral binding, we compared the viral binding with PT cells in the presence or absence of lectins. PT cells were pretreated with 400 mg/mL of MALII, 400 mg/mL of SNA, or both lectins at 400 mg/mL of each lectin, and viral binding was performed at 4°C and bound viruses were visualized by confocal immunofluorescence microscope. The level of virus on the cell surface was also quantified by measuring the fluorescence intensity. Lectin treatment resulted in a significant decrease of viral binding to PT cells (Fig. 6) . This further confirmed that BTV binds cell surface sialic acids during entry.

To address if BTV entry into insect cells also utilizes sialic acids, we similarly examined the distribution of a2,3and a2,6-linked sialic acids on the surface of Culicoides-derived cells (KC). In addition, because mosquito C6/36 cells are also susceptible to BTV infection in the laboratory (17), we included the C6/36 cells in the analysis. Both KC and C6/36 cells appeared to express exclusively a2,6-linked sialic acids, as demonstrated by immunofluorescence staining with the specific lectins (Fig. 7A) . Further, BTV infection of these cells in the presence of the two inhibitors confirmed further that MALII, the inhibitor of a2,3-linked sialic acids had almost no inhibitory effect, while SNA, the inhibitor of a2,6-linked sialic acids, inhibited 90% of progeny virus production in a dose-dependent manner (Fig. 7B) . To eliminate the possibility that the effect was due to cell cytotoxicity, we performed the MTT assay, which showed no impact on the viability of cells (Fig. 7C) . These data suggest that BTV utilizes a2,6-linked sialic acid for entry into the KC and C6/36 cells.

Taken together, the data demonstrate that a2,3and a2,6-linked sialylated glycans play a major receptor role for BTV entry in both mammalian and insect cells. However, the role of other receptors cannot be excluded, particularly for KC and C6/36 cells, as previous studies have indicated that VP2 is not essential for infection and that the integrin binding RGD motif present on the VP7 protein could be responsible for the process (18, 19) .

Putative sialic acid binding sites of VP2 revealed by mass spectrometry analysis. In order to locate the sialic acid binding sites on VP2, hydrogen deuterium exchange mass spectrometry (HDX-MS) was used. Deuterium exchange with hydrogen atoms in VP2 protein prepared in D 2 O buffer, followed by quenching, proteolysis, and peptide detection by MS allows an assessment of the dynamic change of VP2 protein conformation upon SA binding. Purified VP2 was incubated with 39-sialyl-N-acetyllactosamine (Neu5Aca2,3Galb1-4GlcNAc) and digested by pepsin and aspergillopepsin prior to HDX-MS analysis. After carefully optimizing the quenching condition, a total number of 126 peptides were identified, yielding an overall VP2 sequence coverage of 63.1% (Fig. 8A) . Ligand-induced alteration of the H/D exchange rate was only observed in two peptides, peptide 114-124 (DAQPLKVGLDD) of VP2 was deprotected, while peptide 185-194 (VAYTLKPTYD) was protected in the presence of the glycan, suggesting that peptide VAYTLKPTYD is involved in sialic acid binding (Fig. 8B) . To confirm the data, we introduced substitution mutations in this peptide, targeting specifically the two highly conserved residues Y187 and K190 followed by attempted virus rescue by reverse genetics. Of two substitutions at Y187, one to phenylalanine and the other to alanine, only the Y187F mutant was recovered as viable virus. The substitution of Y187A failed to recover the virus. Similarly, mutations at K190 to aspartic acid or to alanine failed to recover infectious progeny virus consistent with Y187 and K190 being critical for virus fitness (Fig. 9A) and also consistent with a role in receptor binding. To verify that these lethal mutations did not alter the overall structure and key function of VP2, mutant proteins Y187A, K190D, and K190A were expressed in BSR cells by transfecting with capped mutant S2 RNA segments. The expression of three mutant proteins and ability to trimerize, was not compromised, indicating that these mutations did not perturb the overall structure of the protein (Fig. 9B) . To substantiate this hypothesis, each of these mutant proteins was expressed as recombinant baculovirus and each purified protein was incorporated into polyvalent nanoparticles. However, none of these three mutant protein nanoparticles showed any hemagglutination activity with sheep RBCs, in contrast to that of the WT or Y187F mutant proteins (Fig. 9C) . These results are consistent with a role for the targeted residues in both SA binding and infection.

BTV generally has very low receptor binding avidity, which is reflected by its low hemagglutinin activity (10) . Thus, the identification of BTV receptor binding using the virus itself or the purified recombinant VP2 protein has been quite challenging. We have circumvented that by successfully generating protein nanoparticle displaying with multivalent presentation of VP2. Such VP2-PNP had significantly enhanced avidity of VP2 interaction with glycans. This is the first tailored design of protein nanoparticle scaffolds for multivalent presentation of a non-enveloped viral glycoprotein, which has been proven a powerful tool for studying of virus-receptor interaction.

We used glycan array to identify that recombinant VP2 binds both a2,3and a2,6linked sialic acids with an overall higher affinity to a2,3-linked sialic acids. During a natural BTV transmission cycle, VP2 mediates BTV binding to sheep erythrocytes via blood (20) . Treatment with MALII resulted in hemagglutination of sheep RBCs but treatment of SNA did not (data not shown). Therefore, the particularly high abundance of a2,3-linked sialic acid on sheep erythrocytes could serve as the primary target of infection.

Glycan array showed that VP2 binds both Neu5Ac and Neu5Gc sialoglycans with a2,3and a2,6-linkage. Trypsin treatment had shown no effect on the ability of BTV hemagglutination of human erythrocytes (21) and the ability of VP2 binding to L929 cells (10) , suggesting that VP2 binds to O-linked glycans containing sialic acids. Despite an overall stronger binding to a2,3-linked sialic acid, inhibition of a2,6-linked sialic acid FIG 8 Legend (Continued) box) and deprotection (hatched red box), respectively, in the presence of the sialoglycan 39-sialyl-N-acetyllactosamine in HDX. Conserved amino acid residues Y187 and K190 within peptide VAYTLKPTYD are predicted to bind sialic acid (red arrow). (C) Predicted sialic acid binding sites (yellow) and residues Y187 and K190 (pink) are located at the tip domains of VP2 trimer. demonstrated a significant effect on progeny virus production in three different mammalian cells corresponding to a predominant distribution of a2,6-linked sialic acid on all three mammalian cell lines. Baby hamster kidney cells (BHK-21) generally express high levels of Neu5Ac and low levels of Neu5Gc, while ovine and bovine cells express high levels of Neu5Gc but less Neu5Ac (22) . All three cell lines could be effectively infected by BTV, though VP2 showed a preference of binding to Neu5Ac sialoglycan. This evidence demonstrates that both linked Neu5Ac and Neu5Gc sialic acids allow efficient virus attachment and entry into host mammalian cells. Moreover, treatment of MALII or SNA or a combination of both lectins effectively prevented viral binding to the surface of PT cells, confirming that both a2,3and a2,6-linked sialic acids are directly involved in virus attachment and entry. Notably, PT cells is more sensitive to the treatment with both lectin competitors targeting a2,3and a2,6-linked sialic acids compared with BSR and MDBK cells. The data was consistent with the immunofluorescence confocal microscopy analysis, which confirmed that there is greater amount of both linked sialic acids on the surface of PT cells; therefore, they are more susceptible to BTV infection. This may also explain why BTV has a wide cell tropism in tissue culture cells. However, the very specific host species tropisms of BTV indicated that there are likely some other factors involved.

Insect cells generally do not produce sialylated glycoproteins (23) . However, the presence of a functional CMP-Sia synthase (CSAS) had been detected in Aedes Aegypti, and dengue virus (DENV) was found to recognize a2,6-linked sialic acid structures on the surface of mosquito tissues, suggesting its potential key roles during the early DENV-vector interactions (24) . Because the complete genomic sequence of Culicoides sonorensis is now available (25), we were able to identify two transcripts CSON006402-1 and CSON006950-1 encoding two 426aa and 427aa undefined proteins, which are predicted to function as beta-galactoside alpha-2,6-sialytransferase by PANTHER algorithm (http:// www.pantherdb.org/). In this study, we demonstrated that both Culicoides KC and Aedes Albopictus C6/36 cells express exclusively a2,6-linked sialic acid, which plays a major role for BTV entry although other putative receptors may be involved.

Our previous structural data predicted the existence of putative sialic acid binding sites on the hub domain of VP2 and other putative binding sites on the tip domain for unknown receptors (5) . Unlike other dsRNA viruses, such as rotavirus or mammalian reovirus (26) , the BTV VP2 trimer has a triskelion shape composed of three tip domains protruding from a central hub domain, which is essential to prevent activation of the underlying membrane penetration protein VP5. Here we identified the peptide VAYTLKPTYD at the interface of body and tip domains protected in the presence of sialoglycan Neu5Aca2,3Galb1-4GlcNAc in the HDX-MS. Therefore, we predicted that the sialic acid binding site is most likely located at the peptide VAYTLKPTYD and may extend into the connecting region in each of the three tip domains (Fig. 8C) . We confirmed the conserved residues Y187 and K190 are critical for sialic acid binding using virus recovery assay in combination with mutagenesis and hemagglutination assay.

This study revealed sialic acids as a functional receptor and the different role of a2,3and a2,6-linked sialic acid for BTV infection in both mammalian cells and insect cells, and also provided biochemical evidence not only to support the structural data but also to reveal dynamic changes of VP2 during receptor binding. Inhibitors targeting specific sialic acid or putative binding sites could be developed as potent antivirals. However, it does not exclude the possibility that other more generic receptors such as heparan sulfate proteoglycan, integrin may also be used by BTV. Whether it is cell or strain dependent remains to be further investigation.

Cloning and protein expression. Synthetic strep-pA-LS and strep-Fc sequences were purchased from Eurofins Genomics. Strep-pA-LS was ligated into the pCAGG-PM1 vector using the PacI/AflII sites. Strep-Fc and BTV1 VP2 sequences (Protein Data Bank accession number: 3J9D) were inserted into the BamHI site of baculovirus transfer vector pAcYM1 by Gibson Assembly (NEB). HEK293 cells were transfected with pCAG-strep-pA-LS using polyethylenimine (PEI). Five days posttransfection, supernatant was collected and the pA-LS protein was purified using the Strep-Tactin Superflow Plus (Qiagen). Recombinant baculovirus expressing Fc-VP2 was generated by cotransfecting the pAcYM1-strep-Fc-VP2 and Bacmid DNA into

Hemagglutination of RBC was visualized as a lack of sedimentation to a distinct red pellet and HA titers were calculated as the reciprocal of the lowest positive dilution. PBS dilution buffer was used as negative control. ELISA based glycophorin binding assay. Ninety-six-well Nunc MaxiSorp ELISA plates (Thermofisher) were coated with 1 mg of glycophorin A (Sigma) per well diluted in 50 ml of carbonate coating buffer (15 mM Na 2 CO 3 , 36 mM NaHCO 3 , pH 9.6) and incubated overnight at 4°C. The plates were washed with PBS with 0.05% Tween 20 (PBST) and blocked with 5% skimmed milk in PBST for 1 h at room temperature. Different amounts of Fc-VP2 alone or Fc-VP2-PNPs complex formed with 2 mg of pA-LS were then added to allow binding to glycophorin A. Bound VP2 was detected with a rabbit anti-VP2 pAb and then alkaline phonsphatase-labeled anti-rabbit secondary antibody (Sigma)

A 30-ml protein solution containing 0.5 mM VP2 and 150 mM 39-sialyl-N-acetyllactosamine (Neu5Aca2,3Galb1-4GlcNAc) in equilibration buffer (10 mM potassium phosphate buffer pH 7.4) was added to 135 ml of deuterated buffer (10 mM potassium phosphate buffer pD7.4) and incubated at 4°C for 60, 120, 600, or 4,200 s. Following the labeling reaction, samples were quenched by adding 50 ml of the labeled solution to 100 ml quench buffer (100 mM potassium phosphate, pH 2.4 with formic acid, 0.2% n-Dodecyl-b-d-Maltopyranoside [DDM]). A 50-ml quenched sample was passed through an online proteolysis column containing a 1:1 mixture of immobilized pepsin and aspergillopepsin (Type XIII protease) (NovaBioAssays, USA) at 500 ml/min and a VanGuard Pre-column Acquity UPLC BEH C18 (Waters Ltd.) for 3 min. The resulting peptic peptides were transferred to a C18 column

HDMS E and dynamic range extension modes (data independent analysis [DIA] coupled with IMS separation) were used to separate peptide prior to CID fragmentation in the transfer cell. HDX data were analyzed using PLGS (v 3.0.2) and DynamX (v 3.0.0) software supplied with the mass spectrometer. Restrictions for identified peptides in DynamX were as follows: minimum intensity 1,000, minimum products per amino acid 0.3, max sequence length 25

Atomic model of a nonenveloped virus reveals pH sensors for a coordinated process of cell entry

Conformation of the VP2 protein of bluetongue virus (BTV) determines the involvement in virus neutralization of highly conserved epitopes within the BTV serogroup

Bluetongue virus entry into cells

Mapping the pH sensors critical for host cell entry by a complex nonenveloped virus

Bluetongue virus coat protein VP2 contains sialic acid-binding domains, and VP5 resembles enveloped virus fusion proteins

Promiscuous viruses-how do viruses survive multiple unrelated hosts?

Human adenovirus type 26 uses sialic acid-bearing glycans as a primary cell entry receptor

Influenza virus entry and infection require host cell N-linked glycoprotein

Rotaviruses preferentially bind O-linked sialylglycoconjugates and sialomucins

Expression and functional characterization of bluetongue virus VP2 protein: role in cell entry

Identification of sialic acid-binding function for the Middle East respiratory syndrome coronavirus spike glycoprotein

A haemagglutination and haemagglutination inhibition test for bluetongue virus

Genetic reassortants for identification of the genome segment coding for the bluetongue virus hemagglutinin

Role of lipids on entry and exit of bluetongue virus, a complex non-enveloped virus

Staphylococcal protein A consists of five IgG-binding domains

Investigating virus-glycan interactions using glycan microarrays

Susceptibilities of 14 cell lines to bluetongue virus infection

VP7: an attachment protein of bluetongue virus for cellular receptors in Culicoides variipennis

RGD tripeptide of bluetongue virus VP7 protein is responsible for core attachment to Culicoides cells

Impact of erythrocyte species on assays for influenza serology

The site of bluetongue virus attachment to glycophorins from a number of animal erythrocytes

Glycosylated biotherapeutics: immunological effects of N-glycolylneuraminic acid

Glycoproteins from insect cells: sialylated or not?

Sialic acid expression in the mosquito Aedes aegypti and its possible role in dengue virus-vector interactions

The genome of the biting midge Culicoides sonorensis and gene expression analyses of vector competence for bluetongue virus

Asymmetric reconstruction of mammalian reovirus reveals interactions among RNA, transcriptional factor micro2 and capsid proteins

We thank Berend-Jan Bosch (Utrecht University, the Netherlands) for the gift of the plasmid expressing nanoparticle, Yi Lasanajak (Emory Comprehensive Glycomics Core, Emory University, USA) for the glycan array, James Ault (University of Leeds, UK) for the HDX-MS, and Ian Jones (University of Reading, UK) for critically reviewing the manuscript. The project was funded by a Wellcome Trust Senior Investigator Award (100218) to P. Roy.